Tag Archives: antigens

Doubts cast on TB blood test

Blood tests designed to detect active TB are inaccurate and should be banned, the World Health Organization has said.

More than two million such tests are carried out annually, but the WHO says they are unethical and lead to misdiagnosis and the mistreatment of patients.

The organisation’s review of these tuberculosis test kits says they give wrong results in around 50% of cases.

The kits are mainly sold in the developing world.

However, most of the 18 kits on the market are produced in Europe and North America.

According to Dr Mario Raviglone, the director of the WHO Stop TB Department, the tests must be banned.

He said: “A blood test for diagnosing active TB disease is bad practice. Tests are inconsistent, imprecise and put patients’ lives in danger.”

The tests work by detecting antibodies or antigens in the blood that are produced in response to the bacterium.

But some of these commercial tests have what’s called “low sensitivity” which leads to large numbers of patients being told they do not have TB when they do.

Tuberculosis

Tuberculosis

Dr Karen Weyer, who is also from the WHO Stop TB department, added: “The evidence we reviewed over the past couple of months shows that one in two patients will be wrongly diagnosed, either [as] false negative or false positive.

“If it’s a false negative patients get the all clear when they in fact have TB, the disease continues to spread, and the patients may die.

“If, on the other hand, it’s false positive, patients are put on treatments unnecessarily while the true cause of their disease remains undiagnosed.”

“We would describe this as unethical – and we are making a very strong urge to governments to consider that TB is a threat and the use of these ineffective tests is also a threat.”

The WHO says that the tests which are manufactured in Europe and North America are prevented from going on sale where they are made due to regulations that call for extensive evidence of accuracy.


But this is not the case in the developing world – including in India and China.

Dr Weyer added: “One of the major problems is that these developing countries often have little or very weak regulatory mechanisms to make sure that tests are registered before they are used at country level.

“Another problem is that these tests are often used in the private sector, which is a difficult sector to regulate and as a result there is a wide misuse, I would say, of these inaccurate tests in the private sector in at least 17 countries that we are aware of.”

She said there was a need for a TB test that could be used “at the bedside”. But she added: “We don’t have a blood test for TB that can be used at the point of care level.”

The WHO says this call for a ban is a highly unusual move – It’s the first time the organisation has issued an explicitly negative policy recommendation against a practice that is widely used in tuberculosis care.

TB kills 1.7m people every year, and is the biggest cause of death of people living with HIV.

Salmonella-based vaccines

Existing vaccines are inadequate for protecting vulnerable populations against fatal diseases, including hepatitis B, tuberculosis, cholera, typhoid fever, AIDS and pneumonia.

Now, Qingke Kong and his colleagues at the Biodesign Institute at Arizona State University have shown how a powerful new class of therapeutics, known as recombinant attenuated Salmonella vaccines (RASV), can make vaccines safer and more effective.

The group, under the direction of Dr. Roy Curtiss, chief scientist at Biodesign”s Center for Infectious Diseases and Vaccinology, demonstrated that a modified strain of Salmonella showed a five-fold reduction in virulence in mice, while preserving strong immunogenic properties.

One of the most promising strategies for new vaccine development is to use a given pathogen as a cargo ship to deliver key antigens from the pathogen that researchers wish to vaccinate against.

Salmonella

Salmonella

Salmonella, the bacterium responsible for food poisoning, has proven particularly attractive for this purpose, as Curtiss explains: “Orally-administered RASVs stimulate all three branches of the immune system stimulating mucosal, humoral, and cellular immunity that will be protective, in this case, against a majority of pneumococcal strains causing disease.”


Recombinant Salmonella is a highly versatile vector—capable of delivering disease-causing antigens originating from viruses, bacteria and parasites.

An attenuated Salmonella vaccine against pneumonia, developed in the Curtiss lab, is currently in FDA phase 1 clinical trials.

The study has been published in the Journal of Immunology.